XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Net sales $ 2,246 $ 1,610 $ 5,129 $ 4,855
Cost of sales 1,784 1,001 3,287 3,255
Gross profit 462 609 1,842 1,600
Operating expenses:        
Research and development, net of grants 2,672 1,826 7,567 5,622
Clinical and regulatory 964 629 3,439 1,927
Selling and marketing 3,040 2,375 8,931 7,057
General and administrative 2,332 2,528 8,208 8,170
Total operating expenses 9,008 7,358 28,145 22,776
Loss from operations (8,546) (6,749) (26,303) (21,176)
Interest income 24 33 67 69
Net loss $ (8,522) $ (6,716) $ (26,236) $ (21,107)
Net loss per common share – basic and diluted (in dollars per share) $ (0.12) $ (0.12) $ (0.41) $ (0.40)
Weighted average common shares outstanding – basic and diluted (in shares) 68,763 56,799 64,113 53,206